Meta-Analysis of SGLT2 Inhibitors in Transthyretin Cardiac Amyloidosis: Insights by Disease-Modifying Therapy
{{output}}
Background: Sodium glucose co-transporter 2 inhibitors (SGLT2i) improve outcomes in heart failure (HF), but evidence in transthyretin cardiac amyloidosis (ATTR-CM)-particularly in patients not receiving disease-modifying therapy ... ...
